NXTC Logo

NextCure, Inc. (NXTC) 

NASDAQ
Market Cap
$36.13M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
642 of 774
Rank in Industry
349 of 432

Largest Insider Buys in Sector

NXTC Stock Price History Chart

NXTC Stock Performance

About NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; …

Insider Activity of NextCure, Inc.

Over the last 12 months, insiders at NextCure, Inc. have bought $0 and sold $0 worth of NextCure, Inc. stock.

On average, over the past 5 years, insiders at NextCure, Inc. have bought $0 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 150,000 shares for transaction amount of $5.51M was made by Sofinnova Venture Partners IX, L.P. (10 percent owner) on 2019‑11‑15.

List of Insider Buy and Sell Transactions, NextCure, Inc.

2019-11-15Purchase10 percent owner
150,000
0.9742%
$36.75$5.51M-7.91%
2019-05-13Purchase
700,000
4.0096%
$15.00$10.5M+82.16%
2019-05-13Purchasedirector
350,000
2.0048%
$15.00$5.25M+82.16%
2019-05-13Purchase10 percent owner
400,000
2.2912%
$15.00$6M+82.16%
2019-05-13Purchasedirector
50,000
0.2864%
$15.00$750,000+82.16%
2019-05-13Purchase10 percent owner
50,000
0.2864%
$15.00$750,000+82.16%
2019-05-13Purchasedirector
125,000
0.716%
$15.00$1.88M+82.16%

Insider Historical Profitability

<0.0001%
ORBIMED ADVISORS LLC
2711013
9.6799%
$1.2910
Khuong Chau Quangdirector
2711013
9.6799%
$1.2910
Sofinnova Venture Partners IX, L.P.10 percent owner
2671856
9.5401%
$1.2920<0.0001%
SHANNON TIMOTHY Mdirector
2254442
8.0497%
$1.2910
CANAAN X L.P.10 percent owner
2254442
8.0497%
$1.2910

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Sofinnova$5.96M9.552.67M0%+$00.01
Logos Global Management Lp$4.29M6.881.93MNew+$4.29M0.46
Affinity Asset Advisors$3.03M4.861.36MNew+$3.03M0.05
OrbiMed$2.54M4.081.14M-57.91%-$3.5M0.02
Millennium Management LLC$2.53M4.051.13M-0.55%-$14,073.53<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.